PCSK9 Inhibitors: all 193 studies that test it
Page 2 of 2. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)CompletedNCT01644175Phase 3Results posted
- Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL DisordersCompletedNCT01624142Phase 2/3Results posted
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying TherapyCompletedNCT01623115Phase 3Results posted
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)CompletedNCT01617655Phase 3Results posted
- A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B GeneCompletedNCT01604824Phase 2Results posted
- Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor AbnormalitiesCompletedNCT01588496Phase 2/3Results posted
- Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedNCT01576484Phase 2Results posted
- Durable Effect of PCSK9 Antibody CompARed wiTh placEbo StudyCompletedNCT01516879Phase 3Results posted
- Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)CompletedNCT01507831Phase 3Results posted
- LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapyCompletedNCT01380730Phase 2Results posted
- Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid LevelsCompletedNCT01375777Phase 2Results posted
- Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant SubjectsCompletedNCT01375764Phase 2Results posted
- Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder StudyCompletedNCT01375751Phase 2Results posted
- Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary HypercholesterolemiaCompletedNCT01288469Phase 2Results posted
- Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin TherapyCompletedNCT01288443Phase 2Results posted
- Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH HypercholesterolemiaCompletedNCT01266876Phase 2Results posted
- Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a StatinCompletedNCT01133522Phase 1Results posted
- Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.CompletedNCT07545226Phase 1
- A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaActive, not recruitingNCT07477704Phase 2
- Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous DoseCompletedNCT07422285Phase 1
- Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Controlled TrialCompletedNCT07295366Phase 4
- A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)Active, not recruitingNCT06284564Phase 2
- Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial HypercholesterolemiaCompletedNCT06231459Phase 4
- Evolocumab in STEMIActive, not recruitingNCT06081803Phase 3
- Safety and Efficacy of Evolocumab in Ischemic StrokeStatus unknownNCT05697185Phase 4
- Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCICompletedNCT05661552Phase 4
- Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCITerminatedNCT05613426Phase 4
- The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI PatientsStatus unknownNCT05579418Phase 4
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell LungActive, not recruitingNCT05553834Phase 2
- Alirocumab in Patients with SepsisCompletedNCT05469347Phase 1
- Alirocumab and Plaque Burden In Familial HypercholesterolaemiaCompletedNCT05465278Phase 4
- EVOLVE-MI: EVOLocumab Very Early After Myocardial InfarctionActive, not recruitingNCT05284747Phase 4
- Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug ProductCompletedNCT05234775Phase 3
- Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD PatientsCompletedNCT05004675Phase 3
- Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial AtherosclerosisActive, not recruitingNCT05001984Phase 2
- Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCIActive, not recruitingNCT04951856Phase 4
- Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19CompletedNCT04941105Phase 3
- The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics EvaluationCompletedNCT04937413Early Phase 1
- Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C ReductionActive, not recruitingNCT04806893Phase 3
- Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C ReductionActive, not recruitingNCT04797247Phase 3
- Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD PatientsCompletedNCT04790513Phase 3
- CARotid plaqUe StabilizatiOn and Regression With Evolocumab.Status unknownNCT04730973Phase 4
- PCSK 9 Inhibition as Secondary Prevention in Renal Transplant PatientsCompletedNCT04665830Phase 3
- Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With HypercholesterolemiaStatus unknownNCT04659525Phase 4
- Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and TreatmentStatus unknownNCT04613167Not applicable
- A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomyStatus unknownNCT04539223Phase 4
- Evolocumab In Advanced Chronic Kidney Disease TrialWithdrawnNCT04510844Phase 4
- Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant PatientsStatus unknownNCT04397653Phase 4
- Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing CoronarographyStatus unknownNCT04338165Phase 2
- Effect of Evolocumab in Patients With Critical Limb Ischemia (Evol-CLI)Status unknownNCT04306471Phase 4
- Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial DiseaseStatus unknownNCT04306081Phase 4
- Early Treatment With Evolocumab in Patients With ST-elevation Myocardial InfarctionWithdrawnNCT04303377Phase 2
- Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 AntibodyCompletedNCT04141579Not applicable
- PCSK9 Inhibitor Treatment for Patients With SPG5Status unknownNCT04101643Phase 1/2
- Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary SyndromeStatus unknownNCT04100434Phase 4
- The CHORAL Flow StudyTerminatedNCT04073134Phase 4
- Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFHCompletedNCT04034485Phase 3
- EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 TrialCompletedNCT03932721Phase 4
- Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)Status unknownNCT03931161Phase 4
- Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass SurgeryCompletedNCT03900026Phase 4
- Evolocumab for PCSK9 Lowering in Early Acute Sepsis (The PLEASe Study)Status unknownNCT03869073Phase 2
- Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary PerfusionWithdrawnNCT03851263Phase 4
- Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial DysbetalipoproteinemiaStatus unknownNCT03811223Phase 4
- EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF PilotCompletedNCT03791593Phase 2
- Early Alirocumab to Reduce LDL-C in Myocardial InfarctionWithdrawnNCT03750760Phase 4
- Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant RecipientsCompletedNCT03734211Phase 3
- Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCICompletedNCT03718286Phase 2
- Treatment of Severe Infection With Antihyperlipidemia DrugStatus unknownNCT03634293Phase 2/3
- The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence TomographyStatus unknownNCT03552432Phase 4
- The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot TrialTerminatedNCT03542110Phase 4
- Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular UltrasoundStatus unknownNCT03529253Phase 4
- Alirocumab in Patients on a Stable Dialysis RegimenStatus unknownNCT03480568Phase 3
- Evolocumab Versus LDL Apheresis in Patients With HypercholesterolemiaCompletedNCT03429998Phase 3
- Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV DiseaseStatus unknownNCT03355027Not applicable
- Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 DiabetesCompletedNCT03344692Phase 3
- EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)CompletedNCT03287609Phase 3
- Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)CompletedNCT03207945Phase 3
- Vascular Effects of Alirocumab in Acute MI-PatientsCompletedNCT03067844Phase 3
- Alirocumab and Reverse Cholesterol TransportCompletedNCT03014830Phase 1
- Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic SyndromeTerminatedNCT03004001Phase 2
- Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With AlirocumabStatus unknownNCT02992301Phase 4
- A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese SubjectsCompletedNCT02979015Phase 1
- A Trial of Alirocumab and Plaque Regression in Peripheral Arterial DiseaseCompletedNCT02959047Phase 4
- Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-CholesterolCompletedNCT01959971Phase 1
- Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy SubjectsCompletedNCT01785329Phase 1
- Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy SubjectsCompletedNCT01670734Phase 1
- Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy VolunteersCompletedNCT01448317Phase 1
- Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)CompletedNCT01448304Phase 1
- Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)CompletedNCT01448239Phase 1
- Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy SubjectsCompletedNCT01443650Phase 1
- Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant AtorvastatinCompletedNCT01161082Phase 1
- Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy VolunteersCompletedNCT01074372Phase 1
- Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy VolunteersCompletedNCT01026597Phase 1